- Advertise
- Contact Us
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Practical Cardiology. All rights reserved.
Heart Disease and Diabetes
The Practical Cardiology™ Heart Disease and Diabetes clinical resource center offers readers the latest in the field of diabetes and cardiovascular disease. With the field of cardiometabolic health becoming a focal point in the fight against cardiovascular disease, this page will host content related to the latest FDA approvals, studies, guideline update, and clinical perspectives from advisory board members.
Arterial Stiffness a Better Predictor of T2D Risk than Blood Pressure in Chinese Patients
May 16, 2022
An analysis of data from more than 11,000 patients in China suggests arterial stiffness could be a better predictor of type 2 diabetes risk than other traditional risk factors, such as hypertension.
Early Glycemic Control Can Help Stave Off Cardiovascular Risk in Type 2 Diabetes
May 12, 2022
A retrospective analysis of more than 25k patients with type 2 diabetes details the impact achieving early glycemic control can have on the risk of cardiovascular disease events among these patients.
Uncontrolled Blood Pressure, HbA1c Common Among Hospitalized Heart Failure Patients
May 09, 2022
An analysis of NHANES surveys from 2001-2018 describes the overall prevalence of uncontrolled hypertension and HbA1c in adults with heart failure and provides insight into racial/ethnic disparities in prevalence.
SGLT2 Inhibitor Prescriptions Increasing Among Cardiologists, Still Room for Improvement
April 28, 2022
An analysis of national prescription data suggests the number of prescriptions for SGLT2 inhibitors from cardiologists increased 12-fold from 2015 to 2020 while prescriptions for GLP-1 RAs increased 4-fold during the same period.
Cognitive Impairment in Diabetes Could Increase Risk of Cardiovascular Disease
April 25, 2022
An analysis of the REWIND trial suggests baseline cognitive impairment was associated with a 1.6 times greater risk of major adverse cardiovascular events among patients with type 2 diabetes.
Plant-Based Diets Can Reduce Risk of Type 2 Diabetes
April 15, 2022
A diet composed of healthy, plant-based foods is associated with a lower risk of developing type 2 diabetes, according to a recent study from the Harvard T.H. Chan School of Public Health.
Finerenone Provides Consistent Benefit for Reducing CV Risk, Regardless of CVD History
April 09, 2022
A prespecified analysis of FIDELITY presented at ACC.22 details the effects of finerenone on reducing cardiovascular risk based on whether or not patients had a history of atherosclerotic cardiovascular disease at baseline.
Sotagliflozin Reduces Stroke, MI, and CV Death, Regardless of CVD History
April 04, 2022
Deepak Bhatt, MD, MPH, breaks down data from the SCORED trial presented at ACC.22, which demonstrated sotagliflozin provided significant benefit in terms of reducing total MACE, total MI, and total stroke, regardless of whether a patient had a history of cardiovascular disease.
Deepak Bhatt, MD, MPH: Estimating the Potential US Patient Population for Finerenone
April 04, 2022
We sat down with Deepak Bhatt, MD, MPH, at ACC.22 to discuss a study he took part in assessing the potential patient population of finerenone using eligibility criteria from FIDELIO-DKD and FIGARO-DKD against information from NHANES.
Combination Therapy with SGLT2i and GLP-1 RA Well-Tolerated, Further Reduces MACE
April 03, 2022
Viet Le, PA-C, discusses a study he led examining the tolerability and clinical impact of initiating combination therapy with SGLT2 inhibitors and GLP-1 RAs compared to monotherapy with either agent within Intermountain Healthcare.